Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203236 | 0.89 | MMP13 (0.38) | HCRTR2HCRTR1LTB4R2LMNA | |
| SCHEMBL201129 | 0.89 | HCRTR1 (0.41) | HCRTR2HCRTR1LTB4R2LMNASLC6A3 | |
| SCHEMBL200750 | 0.86 | HCRTR1 (0.39) | HCRTR2HCRTR1LTB4R2LMNASLC6A3 | |
| SCHEMBL200867 | 0.85 | HCRTR1 (0.40) | HCRTR2HCRTR1LTB4R2LMNAKDM4E | |
| SCHEMBL202381 | 0.84 | HCRTR1 (0.40) | HCRTR2HCRTR1LTB4R2LMNASLC6A3 | |
| SCHEMBL200952 | 0.84 | HCRTR1 (0.40) | HCRTR2HCRTR1LTB4R2LMNAKDM4E | |
| SCHEMBL202562 | 0.84 | HCRTR1 (0.40) | HCRTR2HCRTR1LTB4R2LMNAKDM4E | |
| SCHEMBL200939 | 0.84 | HCRTR1 (0.40) | HCRTR2HCRTR1LTB4R2LMNASLC6A3 | |
| SCHEMBL202992 | 0.78 | HCRTR1 (0.40) | HCRTR2HCRTR1LMNAKDM4E | |
| SCHEMBL202594 | 0.77 | HCRTR1 (0.39) | HCRTR2HCRTR1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-1963262-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007069020-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | HCRTR2 1892/4885HCRTR1 1201/4885LTB4R2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.